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Background: There is growing agreement that reg-
ulators performing beneﬁt–risk evaluations should take
patients’ and caregivers’ preferences into consideration.
The Patient-Focused Drug Development Initiative at the
US Food and Drug Administration offers patients and
caregivers an enhanced opportunity to contribute to
regulatory processes by offering direct testimonials. This
process may be advanced by providing scientiﬁc evi-
dence regarding treatment preferences through engage-
ment of a broad community of patients and caregivers.
Objective: In this article, we demonstrate a
community-engaged approach to measure caregiver
preferences for potential beneﬁts and risks of emerging
therapies for Duchenne muscular dystrophy (DMD).
Methods: An advocacy oversight team led the
community-engaged study. Caregivers’ treatment pref-
erences were measured by using best–worst scaling
(BWS). Six relevant and understandable attributes
describing potential beneﬁts and risks of emerging
DMD therapies were identiﬁed through engagement
with advocates (n ¼ 5), clinicians (n ¼ 9), drug
developers from pharmaceutical companies and
academic centers (n ¼ 11), and other stakeholders
(n ¼ 5). The attributes, each deﬁned across 3 levels,
included muscle function, life span, knowledge about
the drug, nausea, risk of bleeds, and risk of arrhyth-
mia. Cognitive interviewing with caregivers (n ¼ 7)
was used to reﬁne terminology and assess accept-
ability of the BWS instrument. The study was imple-
mented through an online survey of DMD caregivers,Accepted for publication April 9, 2014.
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624who were recruited in the United States through an
advocacy group and snowball sampling. Caregivers
were presented with 18 treatment proﬁles, identiﬁed
via a main-effect orthogonal experimental design, in
which the dependent variable was the respondents’
judgment as to the best and worst feature in each
proﬁle. Preference weights were estimated by calculat-
ing the relative number of times a feature was chosen
as best and as worst, which were then used to estimate
relative attribute importance.
Results: A total of 119 DMD caregivers completed
the BWS instrument; they were predominately biological
mothers (67.2%), married (89.9%), and white (91.6%).
Treatment effect on muscle function was the most
important among experimental attributes (28.7%), fol-
lowed by risk of heart arrhythmia (22.4%) and risk of
bleeding (21.2%). Having additional postapproval data
was relatively the least important attribute (2.3%).
Conclusions: We present a model process for
advocacy organizations aiming to promote patient-
centered drug development. The community-engaged
approach was successfully used to develop and imp-
lement a survey to measure caregiver prefe-
rences. Caregivers were willing to accept a serious
risk when balanced with a noncurative treatment, ev-
en absent improvement in life span. These preferences
should inform the Food and Drug Administration’s
beneﬁt–risk assessment of emerging DMD therapies.
This study highlights the synergistic integration of
traditional advocacy methods and scientiﬁc approach
to quantify beneﬁt–risk preferences. (Clin Ther.Scan the QR Code with your phone to obtain
FREE ACCESS to the articles featured in the
Clinical Therapeutics topical updates or text
GS2C65 to 64842. To scan QR Codes your
phone must have a QR Code reader installed.
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INTRODUCTION
Duchenne muscular dystrophy (DMD) is a rare, life-
threatening, inherited neuromuscular disorder that oc-
curs in male subjects with an incidence of 1.3 to 2.9 per
10,000.1,2 Diagnosis usually occurs around age 5 years,
when differences in motor function become apparent,
but symptoms may appear as early as infancy.3,4 The
condition is associated with signiﬁcant care-related5,6
and ﬁnancial burden.7–9 Affected individuals have pro-
gressive muscular weakness, loss of ambulation that
typically occurs in the teen years, and premature death.3
The mean age of death is in the 20s and is commonly
caused by respiratory failure or cardiac disease.3,4
Currently, there are no therapies approved by the
US Food and Drug Administration (FDA) for DMD.
The standard-of-care treatment is the off-label use of
corticosteroids, which have been shown to stabilize
muscle strength, delay loss of ambulation by 2 to 5
years, improve cardiopulmonary function, and en-
hance quality of life.3,10–12 Several potential therapies
are under clinical trial that target a variety of primary
and secondary effect pathways.13
Similar to other conditions (including other rare
diseases14 and early-on in the HIV epidemic),15
patients and caregivers managing DMD seek to
accelerate approvals for drugs that may save lives.16
In the context of serious, rare disorders with limited
treatment options, patients and patient advocates
want regulators to be more permissive.17 Drugs
under trial for DMD represent a signiﬁcant opport-
unity for families to intervene, and in public forums,
some parent advocates have demanded access to
drugs, even absent conclusive data on efﬁcacy and
safety.18 DMD provides an appealing model for
assessing inﬂuences on treatment decision making
for serious, progressive disorders. The natural
history may lead to high-pressure decisions regarding
the use of novel therapies. The pediatric onset pro-
vides additional complexity, as the majority of treat-
ment decisions are made by parents/guardians who
are also the primary caregivers. These decisions may
later be re-evaluated by adolescent and adult DMDMay 2014patients who could have different treatment
preferences.19
There is growing agreement that regulatory beneﬁt–
risk evaluations should be informed by the perspectives
of patients and caregivers who will ultimately make
treatment decisions and bear the associated risks.20 To
that end, in 2012, the FDA was congressionally
mandated to engage patients to understand the
impact of disease though the Patient-Focused Drug
Development Initiative.21 Although this program offers
patients and caregivers an unprecedented opportunity
to contribute to the regulatory process, the program is
limited in scope and approach, with initially only 20
disease areas being targeted for public comment
involving direct engagement with patients and
caregivers.22 Advocates who do not represent 1 of the
20 chosen disorders are left with little guidance about
how to provide input that is acceptable and useful to
the FDA. Existing models for FDA engagement are
largely limited to providing testimonial. Although such
direct engagement is a primary strength and a mainstay
of advocacy organizations’ efforts to inform decision
makers about their community’s needs and per-
spectives,23 there are limitations to focusing only on
patient and caregiver testimonials, such as questions
about how well those providing testimonial represent
the views of the entire patient population.20,24,25
Increasingly, decision makers are being asked to con-
sider alternative methods to quantify treatment prefer-
ences and risk tolerance that take into account the
views of large groups of stakeholders.26 Draft FDA
guidance has indicated a willingness to incorporate
such evidence into the regulatory process.27 Quanti-
tative preference elicitation methods allow stakeholders
to introduce formal evidence-based decision making
into the regulatory process and have been used to
explore decision making and preferences among a
variety of patient populations.20
The purpose of the present study was to demon-
strate a process by which a patient advocacy organ-
ization might develop scientiﬁc evidence on treatment
preferences. We aimed to model a replicable,
community-engaged approach to exploring preferen-
ces in a large sample of decision makers. Speciﬁcally,
our goal was to explore caregiver preferences for
emerging treatments for DMD. This study is not only
informative to those seeking to understand the
treatment preferences and risk tolerance of DMD
caregivers, but it serves to highlight principles of625
Clinical Therapeuticspatient-centered outcomes research28 by illustrating
how an advocacy organization can take leadership in
generating policy-relevant evidence.
MATERIALS AND METHODS
Parent Project Muscular Dystrophy (PPMD), an ad-
vocacy organization focused on ﬁnding a cure for
DMD, led the study. The advocacy oversight team
comprising PPMD staff members (a clinician, a scien-
tist experienced in drug development, and 2 caregivers
of individuals with DMD) collaborated with the
research team to design and implement the study.
The oversight team made study decisions through a
consensus process. Consistent with the preferences of
PPMD, the authoring research team was a smaller
team of PPMD staff and academic collaborators.
The teams began by deﬁning a research question
about treatment preferences based on the stated needs
of the Duchenne community; they then identiﬁed the
study population (caregivers of individuals with
DMD) and a recruitment strategy. The teams choose
a stated preference method (described under the head-
ing “Methods”) that ﬁt the study needs. In the
development of the treatment experiment (described
under the heading “Identifying Attributes and Lev-
els”), the team used a community-engaged approach
involving multidisciplinary stakeholder informants.
The survey was piloted by a small group of end-
users (described under the heading “Survey Pilot:
Cognitive Interview”), and it was modiﬁed based on
their input. Preliminary and ﬁnal analyses were re-
ported to regulators, industry, and the Duchenne
community in an accessible and timely manner.
Methods
Methods to measure the preferences of patients,
caregivers, and other stakeholders are now well estab-
lished29,30 and are increasingly being applied to study
beneﬁt–risk preferences.20 Although good research
practices have been created to aid in the development
of stated preference applications in medicine,31 appro-
aches such as conjoint analysis and discrete choice
experiments remain complex. They require qualitative
skills to appropriately identify attributes and levels and
develop supporting survey text,32 as well as quantitative
skills to design the experiment33 and analyze results.34
The study used best–worst scaling (BWS) case 2, an
emerging stated-preference method that can be used to
scientiﬁcally assess preferences.35 Referred to as the626“proﬁle case,” BWS case 2 presents proﬁles one at a
time to elicit preferences; Flynn et al36 fully described
the method and provide use guidance. BWS has been
recognized as an approach that is easier to design and
analyze than conjoint analysis and discrete choice;
however, this method is relatively novel in the context
of measuring beneﬁt–risk preferences.20 The study
reported here presents a novel use of the BWS case
2.37,38 BWS is thought to be less cognitively demand-
ing on participants than discrete choice or conjoint
experiments.36 In addition, relevant to our aim of
demonstrating a replicable community-engaged model,
BWS beneﬁts from a straightforward analytic appro-
ach, the results of which are consistent with more com-
plex approaches39,40 that may be unfamiliar to many
researchers in the clinical domain. To guide the devel-
opment, implementation, and analysis of our prefer-
ence elicitation instrument, we used the standards
outlined in the International Society for Pharmacoeco-
nomics and Outcomes Research checklist for conjoint
analysis27 and speciﬁc guidance on the use of BWS.34
Identifying Attributes and Levels
BWS case 2 experiments use attributes (representing
topic areas) and levels (representing attribute variables,
such as amount of or impact on the attributes);
Figure 1 presents an example of a BWS case 2 task.
Identiﬁcation of relevant and comprehensible attri-
butes and levels is required for a meaningful study
outcome. We used a stakeholder-informed approach to
identify attributes and levels that were clinically rele-
vant, meaningful, and understandable to caregivers.
The development of attributes and levels was informed
by PPMD’s 20 years of experience with patients and
families; extensive history consulting on, reviewing,
and funding clinical research; and an ongoing inter-
view study of clinical trial experiences.41
PPMD identiﬁed and invited stakeholder inform-
ants to participate (October–December 2012) through
an existing advocacy-facilitated industry roundtable,
PPMD’s grassroots family networks, PPMD’s clinician
database, or after self-nomination following commun-
ity notiﬁcation of the program launch. Stakeholder
informants, including patient/disease advocates
(n ¼ 5), clinicians (n ¼ 9), drug developers from
pharmaceutical companies and academic centers (n ¼
11), and other stakeholders (n ¼ 5), participated in
group or individual sessions. Attributes and levels for
the emerging therapies were proposed and reﬁnedVolume 36 Number 5
Choose the best thing in this treatment by clicking the
circle under “best” and choose the worst thing by
clicking the circle under “worst.” You have to choose a
best thing and worst thing to move on. Remember
that a computer chose the combinations to make the
experiment work, and some of them seem bad. Even
so, please pick the best and worst thing.
Best Treatment
Slows the progression of
weakness
2-year gain in
expected life span
1-year of postapproval drug
information available
Causes loss
of appetite
Increased risk of bleeding gums
and increased bruising
Increased risk of
harmless heart arrhythmia
Worst
Figure 1. Example of best–worst scaling task.
H.L. Peay et al.through iterative rounds of stakeholder engagement.
Industry informants were important to successfully
identify appropriate attributes because of their ability
to forecast beneﬁts and risks of premarket drugs. The
oversight committee incorporated their informative
input while protecting against potential bias.
This approach yielded 420 potential beneﬁt, ad-
verse effect, and risk attributes. Items were grouped
under themes and reﬁned. Several attributes were
rejected by the oversight team for relevance, similarity
to other items, or concerns about the ability of the
target population to understand the attribute. Exam-
ples of attributes that were not chosen are the ability to
participate in day-to-day family activities and risks to
renal and hepatic function. The participation beneﬁt
was considered to be less concrete and treatment-
associated than muscle function, and thus was not
chosen. The clinical implications of renal and hepatic
damage were difﬁcult to describe in a brief and
accessible format. In addition, we chose not to use
quantitative risks in this survey because the average US
adult has only a basic level of quantitative literacy.42
Through a consensus process, the advocacy over-
sight team ultimately selected 6 treatment attributesMay 2014with 3 levels each. The attributes and associated levels
were chosen to be reasonable based on drugs under
trial, with the notable exception that the highest risk
levels represent considerably more risk than has been
associated with drugs under trial, to date. The pro-
posed attribute list was again shared with stakeholder
informants. Based on their input, the ﬁnal items (effect
on muscle function, life span, knowledge about the
drug, nausea, risk of bleeding, and risk of heart
arrhythmia) were chosen by the oversight group and
study team.
The BWS experiment attributes and levels are
presented in Table I. The functional beneﬁts chosen
were “stops the progression of weakness” and “slows
the progression of weakness” because drugs under trial
are unlikely to result in a cure or signiﬁcant
improvement in strength for patients with DMD. The
life span attribute was presented independently of the
weakness attribute because drugs that affect skeletal
muscle may not improve cardiac outcomes in DMD43
and thus may not improve longevity. Caregiver partici-
pants were prompted to separate muscle function from
life span by use of this cardiac example and a sample
task. Given that the quality of evidence and associated
uncertainty may affect preferences, we included an
attribute relating to knowledge about the drug, descri-
bed as the number of years of postapproval data.
Nausea represents a realistic, easily understood adver-
se effect that may result in increasing burden as patients
lose mobility. The choice of bleeding was prompted by
a Phase II DMD trial that was terminated in 2011
(unpublished data). Arrhythmia was chosen as an
attribute that is salient to caregivers because it is part
of the DMD natural history.44
Experimental Design
Following good research practices, we developed
the BWS case 2 experiment to accommodate the 6
attributes with 3 levels each.31 We applied a 3^6
main-effects orthogonal design, identiﬁed from the
SAS database of orthogonal arrays.45 This array
consisted of 18 full-proﬁle combinations of the attrib-
utes and levels, the minimum such number necessary
to ensure no structural relationships (ie, correlations)
between the attributes.33
As illustrated in Figure 1, in each BWS task,
caregivers were presented with one of the treatment
proﬁles and asked to judge which aspects they thought
were the best and the worst. Before completing the tasks,627
Table I. Attribute, levels, and descriptions resulting from stakeholder engagement.
Attributes and Attribute Lvels Additional Description/Explanation in the Survey
Effect on muscle function “How the treatment affects muscle function”
i Stops the progression of weakness “Most people who take this treatment don’t get any
weaker over time.
ii Slows the progression of weakness “Most people who take this treatment continue to get weaker
over time, but more slowly than they would without
treatment.”
iii Does not change progression of
weakness
Lifespan “By this we mean how many extra years of life are expected
because of the treatment.”
i 5 year gain in expected lifespan “5 extra years of life”
ii 2 year gain in expected lifespan “2 extra years of life”
iii No extra gain to expected lifespan “0 extra years, meaning that the treatment may not change the
person’s lifespan at all.”
Knowledge about the drug “Important information about treatments comes after FDA
approval, from tracking people who take the treatment over
time. Tracking helps us better understand beneﬁts, risks,
potential drug interactions, and how the treatment affects
people of different ages and stages of progression. Imagine
that everyone who takes the treatment is tracked.”
i 2 years of post-approval drug
information available
“The treatment has been on the market for 2 years and we have
data from 900 people with Duchenne.”
ii 1 year of post-approval drug
information available
“The treatment has been on the market for one year and we
have data from 200 people with Duchenne.”
iii No post-approval drug information
available
“The treatment has just been approved and no post-approval
data is available.”
Nausea
i No increased chance of nausea
ii Causes loss of appetite “A person taking the treatment loses his/her appetite”
iii Causes loss of appetite with
occasional vomiting
“A person taking the treatment loses his/her appetite and has
occasional vomiting”
Risk of bleeds “Risk of bleeding”
i No increased risk of bleeds
ii Increased risk of bleeding gums and
increased bruising
“Bleeding gums and increased bruising, without increased risk
of more dangerous bleeding”
iii Increased risk of hemorrhagic stroke
and lifelong disability
“Hemorrhagic (bleeding) stroke, which could lead to lifelong
disability in memory and reasoning. People found to have this
risk would have to stop taking the treatment.”
Risk of heart arrhythmia “Risk of heart rhythm problems”
i No increased risk of heart arrhythmia
ii Increased risk of harmless heart
arrhythmia
“Occasional, harmless heart arrhythmia”
iii Increased risk of dangerous heart
arrhythmia and sudden death
“Dangerous arrhythmia, which could lead to surgery to put in a
deﬁbrillator and risk of sudden death. People found to have
this risk would have to stop taking the treatment.”
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all the attributes and levels to be considered in the task
(including warm-up questions where appropriate), de-
tailed instructions, and an explained example task.
Furthermore, we conﬁrmed that these “treatments do
not currently exist” and that we were “interested in
knowing what [the caregiver] would choose if they did.”
As a matter of context, we informed the caregivers that
“we are imagining that these are approved treatments
provided by the doctor, and not treatments given during
a clinical trial” and asked them to “assume that all your
child’s medical bills, including the costs of the treatment,
are covered by health insurance.” We also assured res-
pondents that this “was not a test” and that there were
“no right or wrong answers.” Each task incorporated a
full proﬁle (ie, all 6 attributes were shown) consisting of
a speciﬁc level for each attribute. Preferences were elici-
ted via caregivers making a judgment as to what aspect
constituted the best and then the worst of the treatment.
Survey Instrument
The BWS instrument was included in a broader
survey. In addition to basic demographic questions, to
ensure that the study sample did not represent individ-
uals with unusually high risk-taking personality traits,
the participant section included the 6-item risk-taking
measure comprising items from the Jackson Personality
Inventory.46 The previously published mean (SD) score
for a physician group was 19 (4), with a range of 11 to
30. We also sought to describe caregivers’ numeracy by
using the 3-item short form (SNS-3) of the Subjective
Numeracy Scale (SNS).47 Poor numeracy has been
associated with ability to evaluate risks and beneﬁts of
health options48 and to negatively affect utility
assessment.49 Previous research has determined a norm
mean score for the SNS of 4.03 (1.04), with a range of 1
to 6.50 Information collected about the affected children
included the number of children with DMD, age, where
the children lived, a mobility item (with 11 responses
ranging from independent walking outdoors to
remaining in bed) that represents disease progression,
insurance type (private vs government), and whether the
children ever experienced a life-threatening emergency.
Survey Pilot: Cognitive Interviewing
Cognitive interviews with 7 parents of individuals
with DMD of varying ages and disease stages were
used to assess comprehension, reﬁne terminology, and
explore the acceptability of the instrument. TheMay 2014investigator (H.L.P.) observed the survey experience
of the interviewees by using videoconferencing. Inter-
viewees were asked to “think aloud” as they completed
the survey, and the investigator used verbal probes to
explore anticipated problem areas, assess understand-
ing of the survey elements, and evaluate willingness to
trade among the attributes and levels. The instrument
was then modiﬁed to the ﬁnal version based on pilot
test feedback, again using a consensus process involv-
ing the study team and the advisory group.
Participants and Recruitment
Participants were caregivers (parents or guardians)
of at least 1 living child with DMD. The caregivers
lived in the United States, were at least 18 years of age,
and were able to complete an online survey in English.
Their affected child could be any age or at any stage of
the disease. The survey was administered online by
using the Qualtrics survey system (Qualtrics, LLC,
Provo, Utah) from January 17, 2013, to February 21,
2013. In the study advertisements, PPMD committed to
sharing the information learned from the survey back
to the DMD community. Recruitment occurred with
the use of newsletter notices, social media, recruitment
e-mails from PPMD, the DuchenneConnect self-report
registry, and through word-of-mouth recruiting. The
anonymous survey was determined to be exempt by the
Western Institutional Review Board (no. 1-756840-1).
Statistical Analysis
In BWS, the dependent variable is the participants’
judgment about the best and worst feature in each
proﬁle presented to them.51 Although the results from
a BWS can be estimated by using complicated
techniques such as conditional logit52 or hierarchical
Bayes,53 one of the beneﬁts of the method is that it can
be analyzed very simply. The simplest techniques
focus on the number of times a particular level of an
attribute was chosen as best and as worst when it was
available in the choice task (unpublished data). A
relative best-minus-worst (BW) score can be calculated
by subtracting the number of times a feature was
chosen as worst from the number of times it was
chosen as best, then dividing by the total number of
times it was available to be chosen. Early applications
of this method have demonstrated a very high level of
correlation between such simple techniques and more
complicated regression-based techniques.39,40 As with
all techniques used to estimate ordinal, multinomial629
Clinical Therapeuticsoutcomes, our scoring approach assumes equal spac-
ing between things that were chosen as best (BW
score, 1), those that were not chosen (BW score, 0),
and those chosen as worst (BW score, –1).
We chose to estimate the importance weights for
each level by using the relative BW score because it
could be easily understood by the broadest readership
(including the community of patients and caregivers
that we engaged in developing this survey). In addition
to the simplicity of the BW score, this approach has
several advantages. First, regression-based techniques
require the use of the omitted category39 or the use of
complex effects coding procedures40 to estimate cho-
ice models. Second, by using this simple approach, we
have ensured that all estimated parameters remain on
the same ratio scale. This method allows comparisons
to be made across the attributes, as well as identi-
ﬁcation of global best and worst attribute levels
across all the attributes. Because the BW score is
estimated as a mean across the sample, we also report
the SEs for these means. This process allows us to
conduct t tests to determine whether the scores were
signiﬁcantly different from zero. We did this for each
attribute level and have reported the P values for
each test.
Finally, we used the relative BW score for each level
within each attribute to assess the overall importance
of each attribute, conditioned on the levels chosen.54
With this technique, relative attribute importance was
estimated by subtracting the lowest relative BW score
associated with a level of that attribute from the
highest relative BW score associated with a level of
that attribute. We then divided each difference by the
sum of all differences across the 6 attributes and
reported the result as a percentage.
RESULTS
A total of 124 caregivers who self-identiﬁed as being a
parent or guardian of an individual with DMD began
the treatment experiment. Two individuals dropped
out after the ﬁrst treatment task; 1 dropped out after
the third treatment task; 1 dropped out after the ﬁfth
treatment task; and 1 dropped out after the 15th
treatment task. The remaining 119 caregivers com-
pleted the entire survey.
Table II summarizes the characteristics of the
sample. Caregivers were predominantly white, mar-
ried, biological mothers, and had 1 affected child.
Education level ranged from high-school or General630Educational Development diploma to graduate or
professional degree; the median response was "4-year
college degree.” Annual household income ranged
from “o$25,000” to “4$100,000”; the median
response was “$75,000 to $100,000.” Caregivers’
ages ranged from 28 to 66 years (mean, 43.7 years),
and the age of the affected children ranged from 2 to
38 years (mean, 12.1 years). Slightly more than one
half of the children were reported as having partici-
pated in clinical research and more than one third in a
clinical trial. Almost all of the affected children lived
in the home of the caregiver (n ¼ 117 [98%]). The
majority of the affected children used private insur-
ance for their medical care (n ¼ 101 [85%]), although
34% (n ¼ 40) endorsed that their child used a state/
government program. Caregivers reported that 19%
(n ¼ 22) of their children had experienced a life-
threatening emergency.
The affected children represented a range of disease
progression. When these children were dichotomized
into an “ambulatory” group, deﬁned as those who
could walk independently outdoors for at least short
distances, and a “nonambulatory” group, deﬁned as
those who could not walk outdoors without help, 75
(64%) were parents with children in the ambulatory
group and 43 (36%) were parents with children in the
nonambulatory group.
The mean (SD) risk-taking score was 17 (4), with a
range of 7 to 30 (higher scores indicate more risk-
taking endorsement). The caregivers in this study
scored signiﬁcantly lower on the risk-taking score
than the physician reference group41 (mean, 19 [4];
P o 0.005), indicating lower risk-taking personality
traits. The mean SNS-3 score was 4.90 (1.1), with a
range of 2.33 to 4.87, which was higher than the
reference population.42 This result was consistent with
the high educational levels reported in our study (68%
with at least a college degree).
Table III presents relative BW scores, SEs, and P
values, and Figure 2 diagrams the relative utility of
each level as measured by using relative BW scores.
All of the BW scores were signiﬁcant at P o 0.001
except for “no increased chance of nausea,” “no
postapproval drug information available,” and “no
increased risk of bleeding.” By a large margin, the
highest utilities as measured by using relative BW
scores were for “stops progression of weakness”
(0.877) and “slows progression of weakness”
(0.800). These scores had almost twice the utility ofVolume 36 Number 5
Table II. Characteristics of participants and
affected children (N¼119)
Characteristic Value
Participant characteristics
Mean (SD) caregiver age, y 43.7 (7.7)
Mean (SD) child age, y 21.1 (6.4)
Caregiver characteristics
Relationship to children
Biological mother 67.2%
Biological father 28.6%
Adoptive mother 3.4%
Adoptive father 0.8%
Marital status
Married/long-term relationship 89.9%
Divorced/separated 9.2%
Widowed 0.8%
Race
White 91.6%
Education
High school/GED 4.2%
Some college 14.3%
Technical school 5.0%
Associated degree 7.6%
4-year college degree 42.9%
Graduate/professional degree 25.2%
Income
o$25,000 5.9%
$25,000–$50,000 8.4%
$50,000–$75,000 18.5%
$75,000–$ 100,000 18.5%
4$100,000 47.1%
Child characteristics
No. of affected children
1 child 92.4%
Z2 children 7.6%
Living arrangements
In caregiver’s home 98.3%
Independent 0.8%
Other 0.8%
Ambulation status
Ambulatory* 63.9%
Nonambulatory 36.0%
Research participation
Clinical research 58.0%
Clinical trial 34.0%
(continued)
Table II. (continued).
Characteristic Value
Had life-threatening emergency
Yes 18.5%
No 81.5%
Note: In some cases, percents do not add to 100%
because of missing values.
GED ¼ General Educational Development diploma.
*Ability to walk independently outside for at least short
distances.
H.L. Peay et al.
May 2014the next-highest score, “5-year gain in expected life
span” (0.464). The “2-year gain in expected life span”
had a similar priority to the “5-year gain in expected
life span” (0.408).
Caregivers attributed the highest negative BW
scores to “increased risk of dangerous heart arrhyth-
mia and sudden death” (–0.786), followed by “in-
creased risk of hemorrhagic stroke and lifelong
disability” (–0.720). This was followed by “causes
loss of appetite with occasional vomiting” (–0.280).
Although the 2 most serious risks had high negative
scores, either (but not both) could be offset by a
treatment that stopped the progression of weakness.
The amount of knowledge about the drug was not
given high relative BW scores at any level, with mean
scores ranging from 0.056 to –0.021.
Table IV includes the relative attribute importance
for the entire group of caregivers. At the attribute
level, effects on muscle function accounted for the
largest proportion of the variance (28.7%), followed
by arrhythmia (22.4%), bleeding (21.2%), life span
(17.3%), nausea (8.1%), and knowledge about the
drug (2.3%).
DISCUSSION
Although the FDA is committed to patient-centered drug
development, the agency has limited resources. Repre-
senting a disease community that was not selected for
the congressionally mandated community engagement
program, PPMD led a study to proactively inform the
FDA’s beneﬁt–risk assessments. The process we used can
be a model for facilitating patient-centered drug develop-
ment through an exploration of the priorities and631
Table III. Best-worst results.
Attribute description Best Worst Best-worst
Relative b-w
Score 5.E. T-test P-Value
Effect on muscle function
Stops the progression of weakness 628 2 626 877 0.013 69.441 o0.001
Slows the progression of weakness 571 0 571 0.800 0.015 53.357 o0.001
Does not change progression of weakness 68 125 57 0.080 0.019 4.149 o0.001
Lifespan
5 veargain in expected lifespan 348 17 331 0.464 0.020 22.741 o0.001
2 veargain in expected lifespan 299 3 291 0.408 0.019 21.186 o0.001
No extra gain to expected lifespan 12 93 81 0.113 0.014 8.269 o0.001
Knowledge about the drug
2 years of post-approval drug info available 109 69 40 0.056 0.019 3.015 0.001
1 year of post-approval drug info available 20 4 16 0.022 0.007 3.288 0.001
No post-approval drug info available 41 56 IS 0.021 0.014 1.524 0.064
Nausea
No increased chance of nausea 19 26 7 0.010 0.009 1.044 0.148
Causes loss of appetite 1 95 94 0.132 0.013 10.272 o0.001
Causes loss of appetite with occasional vomiting 17 217 200 0.280 0.019 14.981 o 0.001
Risk of bleeds
No increased risk of bleeds 3 11 -8 0.011 0.005 2.143 0.016
Increased risk of bleedinggums and increased
bruising
0 190 190 0.266 0.017 16.079 o0.001
Increased risk of hemorrhagic stroke and lifelong
disability
0 514 514 0.720 0.017 42.807 o 0.001
Risk of heart arrhythmia
No increased risk of heart arrhythmia 5 32 27 0.038 0.008 4.498 o0.001
Increased risk of harmless heart arrhythmia 1 122 121 0.169 0.014 11.943 o0.001
Increased risk of dangerous arrhythmia and
sudden death
0 551 561 0.786 0.015 51.131 o0.001
Clinical Therapeuticspreferences of patients, families, and other stakeholders.
Although the individual stories of highly motivated
advocates are powerful and inﬂuential, it is difﬁcult to
know whether these testimonials represent the perspec-
tives of the majority of patients and families. We des-
cribe a successful community-engaged process to under-
stand treatment preferences in a large group of decision
makers supported by the use of best/worst scaling. To
the best of our knowledge, this study represents the ﬁrst
time a patient advocacy organization has led a quanti-
tative preferences study of this complexity, highlighting
a successful advocacy/academic collaboration that inte-
grates traditional advocacy methods, family-centered
outcomes research, and a scientiﬁc approach to quanti-
fying preferences.
Within the context of our experiment, caregivers
attributed very high scores to stopping or slowing the
progression of muscle weakness. Change in life span632was not scored as highly. Feedback during cognitive
interviewing suggested that parents associated better
muscle function with higher quality of life, indicating
that parents value quality more than length of life.
This ﬁnding is consistent with both anecdotal reports
and an interview study of parents of children involved
in clinical trials,41 in which parents expressed a
preference for better quality of life for their child
over a longer life span.
We found that the presence of a serious risk could
be compensated for by a treatment that stops or slows
progression of weakness, even absent any other
beneﬁts. The burden of DMD may be associated with
parents’ willingness to accept a serious risk for a
noncurative treatment. The data support a limit to
parents’ risk tolerance, however: for the levels of
beneﬁt provided in the experiment, they would not
accept a treatment with 2 serious risks.Volume 36 Number 5
1.0
Effect on muscle
function
Life span
Knowledge about
durg
Nausea Risk of bleeding
Risk of heart
arrhythmia
0.8
0.6
0.4
0.2
0.0
R
el
at
iv
e 
B
es
t-
W
or
st
 S
co
re
–0.2
–0.4
–0.6
–0.8
–1.0
Stops
Levels 0.877 0.800 0.464 0.056 0.0220.408 –0.11 –0.02 –0.01 –0.01 –0.03–0.13 –0.26 –0.16–0.28 –0.72 –0.78–0.08
Slows None 5yr 1yr2yr 2yrNone None Mild Mild MildMod Sev SevNone None None
Figure 2. Relative best–worst scores for attribute levels. Mod ¼ moderate; Sev ¼ severe.
H.L. Peay et al.Our community-engaged process contributed to
successful recruitment of sufﬁcient numbers of care-
givers for a complex, time-intensive survey in only 5
weeks, notwithstanding the fact that the study focuses
on a rare disease. The caregivers’ children represented
a range of ages and disease stages, and thus our
outcomes reﬂect the preferences of parents with
children across the disease course. Although the
development of an appropriate experimental design
is a complex task, it is one that is well suited to be ledTable IV. Relative attribute importance.
Attribute Maximum
Effect on muscle function 0.877
Life span 0.464
Knowledge about the drug 0.056
Nausea –0.010
Risk of bleeding –0.011
Risk of heart arrhythmia –0.038
Sum
*Percent relative importance calculated as the difference betwe
divided by the sum of all such differences.
May 2014by advocacy organizations with expert input and
collaboration.
Limitations
There are several limitations to the study. First, the
study sample, although likely to be representative of
caregivers whose children are enrolled in clinical trials,
may not be generalizable to the broader DMD com-
munity. However, we have demonstrated that this
population was not unusually high in risk-takingMinimum Difference Percent*
–0.080 0.957 28.7
–0.113 0.577 17.3
–0.021 0.077 2.3
–0.280 0.270 8.1
–0.720 0.709 21.2
–0.786 0.748 22.4
3.338 100
en the maximum and minimum utility for each attribute
633
Clinical Therapeuticspersonality traits and had adequate numeracy to reduce
concern about numeracy bias in survey responses.
Although the recruitment of caregivers (or patients)
through advocacy groups has a risk of bias, it also has
real beneﬁts over qualitative approaches. Using the
model process, we plan to reﬁne the experiments and
conduct a larger study with a more representative
parent group and a neuromuscular clinician group.
Especially important in our next study is to elicit
treatment preferences from affected teenagers and
adults, anticipating that DMD patients and caregivers
may not assess beneﬁt and risk in the same way.19
Second, although the study used a rigorous ap-
proach to attribute identiﬁcation, the simulated treat-
ments described in the experiment may not represent
the beneﬁt and risk proﬁle of therapies that are
ultimately approved for DMD. As with all stated-
preference experiments, it remains unknown whether
the presence or absence of additional attributes would
inﬂuence the results. On the spectrum of patient
centered to clinically centered speciﬁcation of attrib-
utes, we favored the former to be consistent with the
goals of patient-centered outcomes research and ex-
plore attributes meaningful to our caregiver partic-
ipants. In our future studies, and when more is known
about the beneﬁts and risks of treatment, we aim to
incorporate more clinically centered attributes while
continuing to maintain a priority on utilizing mean-
ingful attributes.
Third, we conducted an aggregate analysis, and
important structures in preference heterogeneity may
have been overlooked. We have previously reported
the differences in treatment preferences by stratifying
data according to child’s ambulation status.55
Although there was a small but signiﬁcant difference
when completing such a stratiﬁcation, this could have
been explained by scale differences between the 2
groups. In follow-up studies, we will aim to have a
larger sample size to allow for both stratiﬁcation and
segmentation analysis,56 which will enable being able
to adequately describe preference heterogeneity.
Fourth, we used a simple technique for estimating
preferences, compared with more advanced regression
techniques. As a supplemental analysis (not reported
here), we reanalyzed our data by using a conditional
logit. One obvious difference between the methods is
that conditional logit requires using effects coding for
each attribute, making each attribute have the same
mean. As such, although each attribute remains on a634ratio scale, the translocation of the origin inherent in
effects coding implies that level importance cannot be
compared across attributes. The advantage of our
simple approach is that all preference weights can be
estimated directly (ie, without using effects coding), and
hence they all sit on the same ratio scale. We modiﬁed
these results to make them comparable to the condi-
tional logit (ie, we subtracted the attribute mean from
each attribute level), and they produced nearly identical
results to the conditional logit, with both methods
having identical ordering (Spearman’s ρ ¼ 1.0) and
near perfect correlation (Pearson’s ρ ¼ 0.997).
Finally, because BWS is a relatively new stated-
preference method, there is the possibility that it may
present a distorted version of preference. However,
there is growing interest in the method given its
simplicity compared with more traditional conjoint
analysis methods, which may affect respondent efﬁ-
ciency (ie, do responses to choice tasks reﬂect respond-
ents true preferences?). We plan to validate these results
against a simple conjoint analysis that was conducted
as part of this study, but more research is needed to
compare BWS and conjoint analysis methods.
Implications
The study ﬁndings are highly relevant to industry
and regulators who are conducting beneﬁt–risk assess-
ments for potential DMD therapies. Emerging results
from clinical trials suggest a slowing of motor decline,
as measured by using the 6-minute talk test, and no
known effect on life span.13 Caregivers’ signiﬁcant
and yet ﬁnite risk tolerance has regulatory implica-
tions as well; however, given the modest risk proﬁle
emerging from many DMD clinical trials, our ﬁnding
of high tolerance for adverse effects and drug-related
uncertainty is also relevant.
This study intended to leverage the FDA’s ongoing
commitment to identifying methods of systematic
patient engagement and, more speciﬁcally, their com-
mitment to the use of statistical methods exploring
and comparing beneﬁts and risks to systematically
quantify patients’ anecdotal reports.57 PPMD was
able to report the outcome of this study to FDA
representatives in both private and public meetings.
Equally important, PPMD reported the results back to
the DMD community through social media, a
webinar, and in-person meetings and conferences. As
the FDA evaluates new drug applications for DMD
therapies, they should be mindful of the value thatVolume 36 Number 5
H.L. Peay et al.parent decision makers place on even moderate
beneﬁts to function, their tolerance for considerable
risk, and their tolerance for uncertainty.
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